Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol‐associated disease etiology

Weigand, Kilian; Peschel, G; Grimm, Jonathan; Luu, Khang; Schacherer, Doris; Wiest, Reiner; Müller, Martina; Schwarz, Herbert; Buechler, Christa

doi:10.1002/eji.202149488

Cited by 6 publications

(9 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies indicated higher serum sCD137 levels in patients with liver cirrhosis [18]. The plasma sCD137 levels of the 30 SIRS/sepsis patients with liver cirrhosis tended to be elevated, though not significantly (p = 0.053; Figure 1b).…”

Section: Plasma Scd137 Levels Of the Sirs/sepsis Patients In Relation...mentioning

confidence: 67%

“…The serum concentrations of sCD137 of patients with acute pancreatitis were also elevated in contrast to healthy controls, and were related to disease severity and mortality [24]. The higher sCD137 of patients with HCV-related liver cirrhosis correlated with serum tumor necrosis factor levels [18].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, sCD137 has shown potential in reducing CD4 T cell activation even without CD137L-expressing cells, suggesting its capability to modulate T cell activity via multiple routes [17]. Excitingly, recombinant sCD137 has been found to temper both Th1 and Th2 polarization, as well as reduce key inflammatory mediators, like tumor necrosis factor, interferon gamma, and interleukin 13, in cell media [18]. Moreover, sCD137 may inhibit the release of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor, by activated monocytes and B cells [5,9].…”

Section: Introductionmentioning

confidence: 99%

“…The serum sCD137 of healthy donors are relatively low, and a pronounced upregulation occurred in the sera of patients with chronic lymphocytic leukemia, autoimmune diseases, or pancreatitis [5,23,24]. The serum sCD137 level of patients with hepatitis C virus and alcohol-related liver cirrhosis also increased [18]. Elevated levels of immunecell-activity-inhibitory molecules may contribute to higher infection rates of patients with chronic liver diseases [25].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients

Räth,

Mester,

Schwarz

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

T cell depletion and functional impairment are characteristics of sepsis. CD137 is a costimulatory receptor on activated T cells, while soluble CD137 (sCD137) inhibits CD137 signaling. This study found elevated sCD137 levels in the plasma of patients with systemic inflammatory response syndrome (SIRS), sepsis, or septic shock compared to healthy controls. The sCD137 levels negatively correlated with the C-reactive protein and positively with procalcitonin and interleukin-6. There was no difference in sCD137 levels based on ventilation, dialysis, or vasopressor treatment. Patients with SARS-CoV-2, Gram-positive, or Gram-negative bacterial infections had similar sCD137 levels as noninfected individuals. Notably, higher plasma sCD137 levels were observed in non-survivors compared to survivors in both the SIRS/sepsis group and the SARS-CoV-2 subgroup. In conclusion, plasma sCD137 levels are associated with severe illness and survival in critically ill patients.

show abstract

Section: Plasma Scd137 Levels Of the Sirs/sepsis Patients In Relation...mentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients

Räth,

Mester,

Schwarz

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“… 34 Moreover, a high level of sCD137 was detected in the serum of HCV and alcohol-associated cirrhosis patients, suggesting that sCD137 does play a role in liver pathologies. 19 …”

Section: Discussionmentioning

confidence: 99%

Detection of sFas, sCD137, and IL-27 Cytokines as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis

Do¹,

Le²,

Nguyen³

et al. 2023

JHC

View full text Add to dashboard Cite

Purpose Hepatocellular carcinoma (HCC), a prevalent type of liver cancer, is mainly diagnosed in the advanced stage, leading to a high mortality rate. Recent advances have identified peripheral cytokines as a potential tool to predict disease outcomes and inform therapeutic decisions. Hence, in this study, we aim to build a predictive model for HCC based on serum levels of different cytokines. Patients and Methods We used immunoassay to quantify the concentrations of IL-27, MIP-1β, Perforin, sCD137, sFas, and TNF-α in the serum of 38 HCC patients and 15 healthy controls. Logistic regression was then used to construct classification models detecting HCC based on these cytokines. A nomogram of the best-performing model was generated to visualize HCC prediction. Results sFas and MIP-1β were found to be significantly higher in HCC patients compared to controls. Predictive models based on cytokine levels combining sFas, sCD137, and IL-27 performed the best in distinguishing HCC patients from healthy controls. This model has a bias-corrected area under the receiver operating characteristic (ROC) curve (AUC) of 0.948, a sensitivity of 92.11%, a specificity of 93.33%, and an accuracy of 0.925. Conclusion Our findings suggest that serum cytokines have the potential to be utilized in HCC screening to improve detection rates.

show abstract

The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis

Yi,

Yan,

Wei

et al. 2024

Eur J Immunol

View full text Add to dashboard Cite

Tuberculosis (TB) was the leading cause of death from a single infectious agent before the coronavirus pandemic. Therefore, it is important to search for severity biomarkers and devise appropriate therapies. A total of 139 pulmonary TB (PTB) patients and 80 healthy controls (HCs) were recruited for plasma soluble CD137 (sCD137) detection through ELISA. Moreover, pleural effusion sCD137 levels were measured in 85 TB patients and 36 untreated lung cancer patients. The plasma cytokine levels in 64 patients with PTB and blood immune cell subpopulations in 68 patients with PTB were analysed via flow cytometry. Blood sCD137 levels were higher in PTB patients (p = 0.012) and correlated with disease severity (p = 0.0056). The level of sCD137 in tuberculous pleurisy effusion (TPE) was markedly higher than that in malignant pleurisy effusion (p = 0.018). Several blood cytokines, such as IL‐6 (p = 0.0147), IL‐8 (p = 0.0477), IP‐10 (p ≤ 0.0001) and MCP‐1 (p = 0.0057), and some laboratory indices were significantly elevated in severe PTB (SE) patients, but the percentages of total lymphocytes (p = 0.002) and cytotoxic T cells (p = 0.036) were significantly lower in SE patients than in non‐SE patients. In addition, the sCD137 level was negatively correlated with the percentage of total lymphocytes (p = 0.0008) and cytotoxic T cells (p = 0.0021), and PTB patients with higher plasma sCD137 levels had significantly shorter survival times (p = 0.0041). An increase in sCD137 is a potential biomarker for severe TB and indicates a poor prognosis.

show abstract

Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol‐associated disease etiology

Cited by 6 publications

References 73 publications

Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients

Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients

Detection of sFas, sCD137, and IL-27 Cytokines as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis

The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis

Contact Info

Product

Resources

About